Purple Biotech Ltd.

Share Issue/Capital Change • Jan 5, 2019

_________ false

����� ����� ��"�	2 352
KITOV PHARMA LTD
Corporation no: 520031238	10994
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C004 ( Public )		Reported via MAGNA:	05/01/2019
	www.isa.gov.il			www.tase.co.il				Reference:	2019-02-001824	Time of broadcast: 21:54 21:47:54

---

Immediate report on other matterDon't use this form if there is more adequate one

Please note that in the case of delayed publication of report, no changes will be allowed after the form is submitted.

	Delay the publication of a report	_________	_________

1. The delay of the report can be done up to 72 hours maximum from the date of filling out the form.2. Attention that in accordance with the provisions of the law, the reporting date must be simultaneous with the report in the foreign exchange.

Revised form of American Depositary Receipt filed with the SEC by BNY Mellon, as Depositary, pursuant to Rule 424(b)(3) under the Securities Act of 1933, to reflect that the ratio of Shares per American Depositary Share has changed from twenty shares to one share. ��� �� ���� ����� ���� �� ����� ����� ����� ������ ������ ���� �� ������ ������ ���� �� �����, ��� ����� ����� �� ����� ������ ���� ��� ����� �� ���� �����, �� �� ����, ����� �� ����� ���� ����� ����� ���� ����� ���� ������ �� ���� �������� ����� ����� ������ ��� ��� ����� �� ���� �����

Attached file kitov424receipt_isa.pdf

The submission by the Company to the Israel Securities Authority and the Tel Aviv Stock Exchange of a copy of a Revised form of American Depositary Receipt filed with the SEC by BNY Mellon, as Depositary, pursuant to Rule 424(b)(3) under the Securities Act of 1933, in order to file the form of American Depositary Receipts that evidence to reflect that the ratio of Shares per American Depositary Share has changed from twenty shares to one share, should not be deemed an admission by the Company that such submission is required of the Company under the Securities Law 5728-1968 and the Securities Regulations (Periodic and Immediate Reports of Foreign Corporation) 5761-2000, nor an admission by the Company that this submission is necessarily being delivered pursuant to the aforesaid laws and regulations.
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
2018-02-128142
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 31/12/2018
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101   , Israel Tel: 03-9333121 , Fax: 03-5097196
E-mail address: info@kitovpharma.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: BEN-TZVI ABRAHAM SHLOMO Position of Signatory in the reporting corporation: Chief Legal Officer & Secretary Name of Employer Company:
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: avraham@kitovpharma.com 1
Israel